Cite
NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
MLA
Ma, Zhenchuan, et al. “NDRG2 Acts as a Negative Regulator of the Progression of Small-Cell Lung Cancer through the Modulation of the PTEN-AKT-MTOR Signalling Cascade.” Toxicology & Applied Pharmacology, vol. 485, Apr. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.taap.2024.116915.
APA
Ma, Z., Ma, Y., Feng, J., Xu, Z., Cheng, C., Qin, J., Li, S., Jiang, J., & Kong, R. (2024). NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade. Toxicology & Applied Pharmacology, 485, N.PAG. https://doi.org/10.1016/j.taap.2024.116915
Chicago
Ma, Zhenchuan, Yuefeng Ma, Jie Feng, Zhengshui Xu, Chuantao Cheng, Jie Qin, Shaomin Li, Jiantao Jiang, and Ranran Kong. 2024. “NDRG2 Acts as a Negative Regulator of the Progression of Small-Cell Lung Cancer through the Modulation of the PTEN-AKT-MTOR Signalling Cascade.” Toxicology & Applied Pharmacology 485 (April): N.PAG. doi:10.1016/j.taap.2024.116915.